Bailey Pemberton
3 min read
Zai Lab (NasdaqGM:ZLAB) is back in focus after early trial data for its lead cancer drug candidate zoci, a fresh equity raise, and third quarter earnings that broadly aligned with market expectations.
The sharp 12.74% 1 day share price return and 15.45% 7 day move suggest traders are reacting quickly to Zai Lab’s zoci data, fresh capital raise, and Q3 update. The 47.03% year to date share price return contrasts with a 5 year total shareholder return that is down 70.08%, indicating strong recent momentum after a difficult longer run.
Scan how traders are repricing oncology risk by comparing Zai Lab with hand picked biopharma names in the 19 high quality undiscovered gems that are still flying under most investors’ radar.
After a jump like this, investors in Zai Lab are really weighing two paths: lean into the rerating now, or hold back and see what the current valuation actually gives you for the risk.
Most Popular Narrative: 24% Undervalued
The most followed narrative on Zai Lab pegs fair value at $33.48 compared with the latest close at $25.48, so the market price currently sits well below that storyline. For anyone watching this latest jump, the key question is whether the business can actually deliver on the global pipeline that underpins that higher value.
The planned shift for Zai Lab from a mainly China-focused commercial business to a global biopharma company, including the first U.S. regulatory submission in 2027 and a potential first U.S. launch in 2028, points to a larger addressable market that could influence long term revenue and earnings.
The updated view highlights zoci and ZL-1503 as clearer lead programs that could shape future revenue mix and margin profile.
See why 13 investors see Zai Lab as 24% undervalued.
Result: Fair Value of $33.48 (UNDERVALUED)
Still, Zai Lab’s reliance on partnered assets and a loss of US$198.4 million on US$441.7 million of revenue keeps execution risk firmly on the table.
Find out about the key risks to this Zai Lab narrative.
Next Steps
The story so far is sending mixed messages. Act while the market is still recalibrating and review both the bull and bear cases for yourself with the 3 key rewards and 1 important warning sign.
Ready for more investment ideas beyond Zai Lab?
Do not stop with a single opportunity. Use the Simply Wall Street Screener to spot other setups that fit your risk, return, and income goals.
-
Target resilient balance sheets by scanning companies in the list of solid balance sheet and fundamentals (24 results) that pair financial strength with room for potential upside.
-
Hunt for mispriced opportunities by reviewing the 39 high quality undervalued stocks that combine quality fundamentals with prices that screens flag as below intrinsic value estimates.
-
Build a steadier income stream by checking out the 8 dividend fortresses that focus on higher yield profiles alongside an emphasis on stability.
